Peanut (Arachis hypogaea L.): A Comprehensive Reference
1. Identity and Botanical Classification
Peanut is a legume crop that belongs to the family Fabaceae, genus Arachis, and is botanically named Arachis hypogaea L. Despite its common name, peanuts are not true nuts; they belong to the legume family. The species is an allotetraploid — a natural hybrid of two wild species that originated in Bolivia. There are six botanical varieties of cultivated peanut and thousands of cultivars, of which the most popular are Spanish, runner, Virginia, and Valencia.
Common synonyms and vernacular names include groundnut (widely used in Africa and Asia), goober, monkey nut, and earth nut. The Bantu name for peanut is nguba, which was later anglicized to "goober." In Nahuatl, the pre-Columbian language of the Aztec peoples, the peanut is called tlalcacahuatl.
Common Forms and Preparations
Peanuts are consumed in many forms such as boiled peanuts, peanut oil, peanut butter, roasted peanuts, and as added peanut meal in snack food, energy bars, and candies. Peanut butter is a food paste or spread made from ground dry-roasted peanuts; it often contains additional ingredients that modify the taste or texture, such as salt, sweeteners, or emulsifiers. Peanut flour is used in gluten-free cooking. Peanut oil, extracted from kernels, is widely used as a cooking medium. Additionally, peanut protein concentrate and isolate powders represent an emerging supplement form, with peanut protein powders typically concentrating the protein content to 50–60% by weight, removing much of the fat and carbohydrates while preserving the amino acid profile.
2. Historical and Traditional Use
Origins in South America
Peanut cultivation originated in the contiguous area of Bolivia, Paraguay, Argentina, and Brazil. Macrofossil and starch grain data show peanuts moved into the Zaña Valley in Northern Peru 8,500 years ago, presumably from the eastern side of the Andes Mountains. The peanut has been found in archaeological sites dating to 1200–1500 BC in coastal Peru.
As early as 1500 BC, the Incans of Peru used peanuts as sacrificial offerings and entombed them with their mummies to aid in the spirit life. Many pre-Columbian cultures, such as the Moche, depicted peanuts in their art. One of the most impressive examples is a necklace with 20 gold and silver peanut replicas found in the burial of the Lord of Sipán in the Reque Valley, a member of the Moche ruling elite. Tribes in central Brazil also ground peanuts with maize to make a drink.
Mesoamerican Use
Historical records establish the presence of the peanut in pre-colonial Mesoamerica, where it gained importance to Nahua peoples of present-day Mexico. Book Eleven of the Florentine Codex portrays a yellow-flowered peanut and documents Indigenous knowledge about its structure and medicinal properties. Cultivation was well-established in Mesoamerica before the Spanish arrived.
Global Diffusion via European Exploration
During the colonial era, Spanish and Portuguese explorers first encountered the peanut in the New World tropics, where Indigenous peoples cultivated it, and subsequently transported the plant to Europe, Africa, Asia, and beyond in the sixteenth century. Portuguese and Spanish traders introduced peanuts all over the world — to Malaysia, China, India, and East and West Africa.
Africans were the first people to introduce peanuts to North America beginning in the 1700s. They were first grown in Virginia and used mainly for oil, food, and as a cocoa substitute; at this time, peanuts were regarded as food for livestock and the poor and were considered difficult to grow and harvest. Peanuts became prominent after the Civil War when Union soldiers found they liked them and took them home; both armies subsisted on this food source high in protein.
Role in Agricultural Development
The rise of peanut production in the US in the early 1900s can be credited to the growing popularity of peanut butter and peanut-based products, a need for plant oils during World War I, and the research of Dr. George Washington Carver, who is considered by many to be the father of the peanut industry and began his peanut research in 1903. He suggested to farmers that they rotate their cotton plants and cultivate peanuts; while cotton depletes nitrogen from the soil, peanuts, as legumes, naturally add nitrogen back into the soil. In 1890, peanut butter was developed as a health food for sick people.
Traditional Nutritional and Therapeutic Uses
Due to their high nutrient content and affordability, peanuts have been used to combat malnutrition in most developing countries. Throughout history, peanuts have been enjoyed in many culinary applications, from Chinese to African to Western cooking. In Africa, peanuts became a central ingredient in many traditional stews and sauces. In Asia, peanut oil became a primary cooking fat. In Mexico, peanuts are used to prepare traditional dishes such as chicken in peanut sauce (encacahuatado).
3. Key Constituents and Active Compounds
Macronutrients
Similar to other nuts, the peanut is an excellent source of nutrients with a substantial amount of lipid, protein, and fiber content along with some amount of carbohydrate, vitamins, and minerals. The ranges of peanut nutrient constituents recently reported were protein 20.7%–25.3%, crude fat 31%–46%, ash 1.2%–2.3%, crude fiber 1.4%–3.9%, carbohydrate 21%–37%, and moisture 4.9%–6.8%. Peanuts provide the highest protein content of all commonly consumed snack nuts and serve as a rich source of heart-healthy, monounsaturated oil, while also providing a variety of healthy micronutrients and bioactive compounds.
Lipid Profile
Peanut oil is composed predominantly of unsaturated fatty acids. The principal fatty acids are oleic acid (a monounsaturated omega-9) and linoleic acid (a polyunsaturated omega-6). The chemical compositions of peanuts are very much affected by cultivar, maturity, year, location, season, agricultural practice, processing, and storage. High-oleic peanut varieties have been specifically bred to increase the proportion of oleic acid, which is associated with greater oxidative stability and potential cardiovascular benefits.
Proteins and Amino Acids
Peanut has a high percentage of arginine (approximately 12.5% of protein), which, when coupled with its overall high protein content, makes peanut an important dietary source of this amino acid whose consumption has been directly linked to various cardiovascular health-promoting activities. Analysis of different peanut protein components indicates that each contains more than 17 kinds of amino acids; the total protein has a relatively high content of aspartic acid, glutamic acid, and arginine and a low content of cysteine, methionine, tyrosine, and lysine. The protein composition in peanuts includes all nine essential amino acids, though the concentrations vary. Peanut protein's limiting amino acids are methionine and lysine relative to animal-based proteins.
Vitamins and Minerals
Peanuts are a rich source of vitamins and minerals, including B vitamins (especially niacin, thiamine, and folate), vitamin E, magnesium, phosphorus, potassium, and zinc. Peanuts provide significant amounts of niacin (vitamin B3), folate, and magnesium; niacin supports energy metabolism and muscle function, while folate aids in protein synthesis and red blood cell formation.
Secondary Metabolites and Bioactive Phytochemicals
Peanuts contain stilbenoids, flavonoids, phenolic acids, phytosterols, triterpenes, and alkaloids. Phenolic compounds such as hydroxybenzoic acid, ferulic acid, coumaric acid, resveratrol, flavonoids (catechin and procyanidins), and flavanols (quercetin and kaempferol) have been identified in peanut kernels.
Resveratrol
Peanuts are an important dietary food source of resveratrol — a naturally occurring stilbene phytoalexin phenolic compound produced in response to a variety of biotic and abiotic stresses — with potent antioxidant properties implicated in reducing the risk of cancer, cardiovascular and Alzheimer's disease, and delaying aging. When plants are exposed to ultraviolet light, oxidative stress, fungal infection, and environmental stress, they produce resveratrol as a defense mechanism in order to resist invasion from the outside. Under natural conditions, resveratrol exists in its trans structure; trans-resveratrol will convert into the cis structure under UV irradiation, but only trans-resveratrol is effective for human absorption. Boiled peanut has been reported as a significant source of resveratrol in comparison to other roasted or raw preparations.
Phytosterols
Phytosterols are a group of naturally occurring compounds found in plant cell membranes; because they are structurally similar to the body's cholesterol, when they are consumed they compete with cholesterol for absorption in the digestive system, blocking cholesterol absorption and thereby reducing blood cholesterol levels. As part of a heart-healthy eating plan, consuming phytosterols in recommended quantities has been shown to lower total cholesterol up to 10% and LDL or "bad" cholesterol up to 14%.
Other Notable Compounds
Bioactive compounds in peanuts, including resveratrol, β-sitosterol, procyanidins, oleic acid, and arachidins, have been found to have the potential to address diseases such as cancer, cardiovascular disease, diabetes, and oxidative stress. New findings suggest that a large number of flavonoids are strong antioxidants that help balance reactive oxidative species, thereby minimizing oxidative stress.
4. Mechanisms of Action
Cholesterol Competition (Phytosterols)
Because phytosterols are structurally similar to the body's cholesterol, when consumed they compete with cholesterol for absorption in the digestive system, blocking cholesterol absorption and reducing blood cholesterol levels. Phytosterol consumption may also increase the activity of antioxidant enzymes and thereby reduce oxidative stress; in addition to altering cell-membrane structure and function, phytosterols probably promote apoptosis by lowering blood cholesterol levels.
Antioxidant and Anti-Inflammatory Pathways (Resveratrol and Polyphenols)
Resveratrol (3,4′,5-trihydroxystilbene), a natural phytoalexin polyphenol, exhibits anti-oxidant, anti-inflammatory, and anti-carcinogenic properties. This compound acts as a phytoalexin, limiting the growth of pathogens and protecting cells from oxidative stress, and when consumed by other organisms, it has the ability to modulate the expression of genes associated with protective mechanisms and the regulation of inflammatory processes. Resveratrol's mechanism of action is thought to primarily involve direct activation of SIRT1, a histone deacetylase of the Sirtuin class. Despite its broad biological activity, the use of resveratrol is limited due to its poor bioavailability and low solubility.
Endothelial and Vascular Function (Arginine)
Peanut's high arginine content makes it an important dietary source of this amino acid, whose consumption has been directly linked to various cardiovascular health-promoting activities. Arginine is a precursor to nitric oxide (NO), a vasodilatory signaling molecule, which supports endothelial function, blood pressure regulation, and blood flow. The cardioprotective effects of nuts are also thought to be achieved by maintaining endothelial function; endothelial dysfunction is a precursor for atherosclerosis and an independent predictor of cardiac events.
Satiety and Weight Regulation
Several mechanisms have been proposed for the lack of weight gain observed with nut consumption despite their high energy and fat content, including reduced energy intake subsequent to increased satiety, energy lost through fecal fat loss, and a possible increase in energy expenditure. Nuts have high satiety value; human feeding trials show that nut intake moderates appetite in the post-meal period, and nuts including peanuts have been shown to suppress hunger and the desire to eat and increase fullness ratings following intake.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Health
Evidence level: Moderate to strong (multiple RCTs and meta-analyses)
Peanuts' role in a heart-healthy diet has warranted tremendous attention among consumer groups and within the scientific community. Multiple lines of clinical investigation support beneficial effects on lipid profiles and cardiovascular risk.
A randomized crossover clinical trial by Damasceno et al. (published in Public Health Nutrition) enrolled 54 hypercholesterolemic men with total cholesterol (TC) concentrations between 200 and 350 mg/dL, who were randomly assigned to two groups and asked to consume peanut supplements (about 77 g) with their habitual diet for 4 weeks. Compared with the habitual diet, peanut supplementation significantly reduced the TC/HDL-cholesterol ratio and LDL-cholesterol/HDL-cholesterol ratio; peanut consumption also increased HDL-C (mean 6.1 mg/dL) and total antioxidant capacity.
A 2022 paper published in Frontiers in Nutrition, combining an RCT (the ARISTOTLE study) with a meta-analysis, found that peanut consumption may improve lipid profiles, as the total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios were lower in the peanut-consuming group after a 6-month intervention; a meta-analysis of nine studies evaluating this cardiovascular risk factor in peanut consumers found a reduction in triglyceride levels after peanut product consumption. Subgroup analyses showed that triglyceride levels were significantly lower after interventions with peanuts and peanut butter, but not high-oleic peanuts.
A large systematic review and meta-analysis of 139 RCTs (published in PMC, 2023) examining tree nut and peanut consumption found that nut consumption was associated with a significant decrease in LDL cholesterol, total cholesterol, triglycerides, TC:HDL cholesterol, LDL cholesterol:HDL cholesterol, and apolipoprotein B. However, the authors noted important limitations: the certainty of the body of evidence for TC:HDL cholesterol, LDL cholesterol:HDL cholesterol, and apoB were "moderate" because of inconsistency, for TG were "low," and for LDL cholesterol and TC were "very low" because of inconsistency and the likelihood of publication bias.
Epidemiological data also support cardiovascular benefit: consuming peanuts two or more times per week was associated with a 13% lower risk of total cardiovascular and coronary heart diseases in two large prospective cohorts of women from the Nurses' Health Study and men from the Health Professionals Follow-Up Study.
5.2 Blood Glucose and Type 2 Diabetes Risk
Evidence level: Moderate (epidemiological data supported by RCT evidence, with caveats)
Moderate consumption of peanuts [1–1.5 ounces/day (28–42 g/day)] has been shown in clinical studies to improve glucose metabolism and the blood lipid and lipoprotein profile, with no increase in body weight. A clinical study in obese men showed that acute consumption of conventional peanuts and high-oleic peanuts (56 g, providing 25% of total energy) attenuated postprandial inflammatory and insulin responses compared with a control meal with no peanuts.
An RCT published in Nutrients (2022) examined the effect of consuming 35 g of peanuts prior to two main meals per day as part of a weight loss diet, compared to a traditional low-fat weight loss diet, on body weight, markers of glycemic control, and blood pressure in adults at risk of type 2 diabetes over 6 months. In total, 107 participants were randomized (65% female; mean age 58 ± 14 years, BMI 33 ± 5.4 kg/m²) and 76 participants completed the study.
Nut consumption has also been associated with a reduced risk of type 2 diabetes; evidence to support this comes from large epidemiological studies. However, the effects of nuts on insulin sensitivity are influenced strongly by changes in body weight, which may account for the changes observed in studies where subjects reduced body weight with nut consumption.
5.3 Body Weight and Adiposity
Evidence level: Moderate (consistent across epidemiological studies and RCTs, though heterogenous populations)
Despite their energy density, peanuts do not appear to promote weight gain. Evidence supports that tree nut and peanut consumption do not influence adiposity, and that compared to a control diet, consumption of almond-enriched diets was associated with reduced waist circumference.
A systematic search of 23 clinical trials investigating the effect of chronic nut consumption (averaging approximately 15%–20% of energy requirements) on body mass demonstrated a small, non-significant weighted mean decrease in body weight of 0.47 kg, BMI of 0.40 kg/m², and waist circumference of 1.25 cm.
From the Nurses' Health Study II, participants who consumed nuts frequently (two or more times per week) had a 31% reduced risk of weight gain, or a 33% lower risk of obesity, than those who rarely or never consumed nuts. Based on the available evidence from prospective studies, also supported by RCTs and cross-sectional studies, long-term nut consumption is associated with lower weight gain and overweight/obesity.
5.4 Antioxidant and Anti-Inflammatory Effects
Evidence level: Preliminary to moderate (mostly in vitro, animal, and limited clinical data)
Some therapeutic effects have been reported for peanut seed extracts, such as antioxidative, antibacterial, antifungal, and anti-inflammatory activities. In vivo and in vitro studies, the biological activities of peanut were found to include anticancer activity, cardiovascular protection, anti-inflammatory, antibacterial, and regulating intestinal flora, among which resveratrol had the most significant biological activity. However, a significant proportion of this evidence comes from cell-culture and animal studies; robust human clinical trials specifically evaluating the anti-inflammatory effects of whole peanut consumption remain limited.
New findings suggest that a large number of flavonoids in peanuts are strong antioxidants that help to balance reactive oxidative species, thus minimizing oxidative stress; these compounds, along with condensed tannins and other polyphenolics, exhibit antioxidant, anti-inflammatory, anti-adiposity, and anti-cancer activities.
5.5 Cancer — Preliminary and Preclinical Evidence Only
Evidence level: Weak/preliminary (largely in vitro and animal studies; no clinical trials establish causation in humans)
High-phenolic and antioxidant-rich peanut genotypes were analyzed using in vitro assay, with LC/MS profiling identifying 11 phenolic compounds such as p-coumaric acid and quercetin associated with antioxidant and chemopreventive effects; extracts from the most bioactive genotypes effectively reduced colon cancer cell viability in vitro, suggesting possible anticancer potential. Phytosterols seem to act through multiple mechanisms of action, including inhibition of carcinogen production, cancer-cell growth, angiogenesis, invasion and metastasis, and through the promotion of apoptosis of cancerous cells. These findings are entirely in vitro or animal-based and cannot be directly extrapolated to human cancer outcomes.
5.6 Nutrition and Malnutrition
Evidence level: Strong (well-established in public health and nutrition literature)
Peanuts, Arachis hypogaea, are one of the most widely consumed legumes globally due to their nutrition, taste, and affordability; they are protein and energy-rich and have been utilized worldwide to address the nutritional needs in developing countries. Ready-to-use therapeutic foods (RUTFs) based on peanut paste are a cornerstone of the WHO-endorsed treatment for severe acute malnutrition in children in resource-limited settings. This is an established application supported by international public health evidence.
6. Body Systems and Health Areas Associated with Peanut
- Cardiovascular system: Lipid profile modulation, endothelial function support (via arginine/nitric oxide), and reduced atherogenic particle profiles are the most clinically supported associations.
- Metabolic system: Improved postprandial glucose and insulin responses; epidemiological associations with reduced type 2 diabetes risk.
- Body weight/adiposity: High satiety despite energy density; consistent evidence of no weight gain with moderate peanut consumption.
- Immune system: Resveratrol exhibits multiple bioactivities including anti-oxidative, anti-inflammatory, cardiovascular protective, and anti-aging properties in animal models. Human data on immune modulation remain limited.
- Musculoskeletal system: Peanut protein provides all essential amino acids including leucine (relevant to muscle protein synthesis) and arginine.
- Gastrointestinal system: Biological activities include regulation of intestinal flora. Dietary fiber in peanuts contributes to gut health.
- Neurological (preliminary): Resveratrol can inhibit amyloid-β-peptide and improve Alzheimer's disease markers in preclinical models; human data are not yet conclusive.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are cited directly from the clinical studies referenced in this article:
- ~77 g/day of peanuts consumed with the habitual diet for 4 weeks — used in a randomized crossover trial in hypercholesterolemic men; significant improvements in lipid ratios and HDL-C were observed.
- 35 g of lightly salted dry-roasted peanuts prior to two main meals per day — evaluated over 6 months in overweight adults at risk of type 2 diabetes in a two-arm RCT.
- 1–1.5 ounces/day (28–42 g/day) — moderate consumption described in clinical literature as associated with improved glucose metabolism and blood lipid profiles with no increase in body weight.
- 56 g (providing 25% of total energy) — used as acute peanut dose in a clinical study in obese men; attenuated postprandial inflammatory and insulin responses.
- Chronic consumption averaging approximately 15%–20% of energy requirements — average intake across 23 clinical trials reviewed in a systematic search, showing non-significant small decrease in body weight, BMI, and waist circumference.
No standardized therapeutic dose has been established by any regulatory authority specifically for peanut as a dietary supplement. The above dosages reflect study-specific protocols and should be interpreted in that context.
8. Safety Considerations
8.1 Peanut Allergy (IgE-Mediated)
Peanut allergy is the leading pediatric food allergy and a common cause of anaphylaxis. The prevalence of current self-reported peanut allergy was 2.9% among US adults, with 1.8% having convincing peanut allergy. In the United States, the prevalence of self-reported peanut allergy increased from 0.4% in 1997 to 1.4% in 2008.
Peanut allergy is an IgE-mediated type I hypersensitivity reaction; in these reactions, initial exposure to an allergenic peanut protein in a susceptible individual leads to the production of protein-specific IgE, which can bind to high-affinity IgE receptors on mast cells and basophils. When re-exposure to the antigen occurs, the peanut allergen binds to peanut-specific IgE, cross-linking cell-bound IgE and triggering degranulation of mast cells and basophils, causing release of preformed allergic mediators such as histamine.
About 20%–30% of food-induced anaphylactic events are characterized by a biphasic response, in which allergic symptoms recur 1 to 8 hours after initial symptoms have resolved; concomitant asthma and delay in administering epinephrine are risk factors for poor outcome of peanut anaphylaxis. In most people with peanut allergy, symptoms develop after substantially less than 1 peanut is ingested, and highly allergic people can react to trace amounts.
Thirteen specific allergic protein components of peanut have been identified and characterized. Ara h 2 is the predominant antigen in peanut-allergic patients in some but not all countries. The prevalence of clinician-diagnosed peanut allergy in infants decreased following the publication of early peanut introduction guidelines.
8.2 Aflatoxin Contamination
A documented and significant safety concern is contamination of peanuts by aflatoxins. Aflatoxins are toxic metabolites produced by Aspergillus flavus, A. parasiticus, and A. nomius; the types presenting the most significant public-health concerns are aflatoxin B1, B2, G1, G2, M1, and M2, which are highly toxic and contain carcinogenic compounds that cause disease in livestock and humans. The International Agency for Research on Cancer (IARC) has classified aflatoxin B1 as a Group 1 human carcinogen.
Aflatoxins, toxic metabolites produced by certain Aspergillus species, can accumulate in peanuts during cultivation, harvest, storage, and processing; these toxins are highly carcinogenic and pose severe health risks, including liver cancer, immunosuppression, and stunted growth in children. Aflatoxins are small, stable molecules that cannot be destroyed by heat treatment or during processing.
There is also increasing evidence that exposure to aflatoxins may cause adverse immune system effects and stunted growth in children. The US Food and Drug Administration (FDA) has set "actionable limits" (maximum tolerable levels of total aflatoxins) for foods like corn and peanuts to control how much aflatoxin can enter foods sold to humans. Aflatoxin levels in peanuts and peanut products from China, Indonesia, Thailand, the United States, and the Philippines were found to be above the safe lower limit margin of exposure of 10,000, indicating an absence of public health or safety risk for the majority of the population in those producing countries.
8.3 Oxalates and Purines
Peanuts contain carbohydrates, lipids, proteins, vitamins, minerals, some organic acids, and purines. Individuals with conditions sensitive to purine intake (e.g., gout) should account for this; however, peanuts are not classified as a high-purine food and are generally well-tolerated in moderate amounts. Peanuts also contain oxalic acid; those prone to calcium oxalate kidney stones should be aware of this, though peanuts are not considered a primary dietary risk factor.
8.4 Sodium in Processed Forms
Raw peanuts and peanuts prepared without salt are naturally low in sodium, having 18 mg of sodium per 100 g. Commercial salted roasted peanuts and commercially processed peanut butter products may contain substantially higher sodium levels, which is a relevant consideration for individuals managing blood pressure.
8.5 Energy Density and Portion Considerations
Peanuts are energy-dense. Nuts are energy-dense and often excluded from weight loss diets. Evidence to date suggests that nut intake does not promote weight gain in studies targeting weight maintenance. However, unrestricted consumption beyond study-defined portions has not been systematically evaluated for weight-neutral or weight-beneficial outcomes.
8.6 Potential Drug and Nutrient Interactions
Peanut oil has been used as an excipient and vehicle in pharmaceutical preparations and may carry trace allergenic peanut proteins, posing a risk to severely peanut-allergic individuals. Peanuts' high content of vitamin K precursor compounds is modest compared to leafy greens, and clinically significant interactions with anticoagulant therapy (e.g., warfarin) from peanut consumption alone are not well-documented in the clinical literature. The monoamine oxidase inhibitor (MAOI) interaction reported for tyramine-containing foods does not specifically implicate peanuts at typical intake levels. Peanut's high phytate content may reduce the bioavailability of minerals such as iron, zinc, and calcium from the same meal, a consideration in populations dependent on peanuts as a primary mineral source.
References
Go back